AKT1 and endometrial cancer: Similar to the other preoperative window studies in breast and endometrial cancer 18,40, we found that metformin significantly decreased phosphorylation of downstream targets of the mTOR pathway, including p-Akt, p-S6, and p-4E-BP-1.